Intro
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) in which the immune system attacks myelin — the insulating sheath that surrounds nerve fibres in the brain and spinal cord. This damages the ability of nerves to conduct electrical signals, producing a wide range of neurological symptoms.
MS is highly variable. Two people with MS may have completely different symptoms, disease courses, and long-term outcomes. This variability makes MS simultaneously unpredictable and — crucially — survivable and manageable for most people with access to modern care.
Approximately 2.8 million people worldwide live with MS. It is most commonly diagnosed between ages 20 and 50, and affects women approximately three times more often than men.
Key Points
- MS is an autoimmune condition causing immune-mediated damage to myelin in the brain and spinal cord
- The most common form is relapsing-remitting MS (RRMS), characterised by discrete attacks followed by partial or full recovery
- Common symptoms include fatigue, vision changes, limb weakness, sensory disturbance, and bladder problems
- Diagnosis uses MRI scanning and the McDonald criteria — there is no single diagnostic test
- Disease-modifying therapies (DMTs) reduce relapse rate and slow progression in RRMS
- Disease course varies enormously — individual prognosis cannot be stated with certainty at diagnosis
- Fatigue is the most common and disabling symptom; it requires specific management strategies
Background: Autoimmune Demyelination
The brain and spinal cord transmit electrical signals via neurons. Myelin — produced by oligodendrocytes — insulates these fibres and allows rapid signal conduction. In MS, autoreactive T lymphocytes cross the blood-brain barrier and attack myelin, triggering inflammation that destroys myelin and, over time, the underlying nerve axons.
The resulting plaques (lesions) are visible on MRI. Where axonal damage occurs, function may be permanently impaired.
The inflammatory response also triggers astrocyte scar formation — hence the name “sclerosis” (hardening/scarring).
Types of MS
Relapsing-remitting MS (RRMS) — ~85% of diagnoses
Characterised by discrete episodes (relapses or attacks) of neurological symptoms lasting days to weeks, followed by partial or complete recovery. Between relapses, the condition is stable (remission). Over time, incomplete recovery from relapses can lead to gradual accumulation of disability.
Most people initially diagnosed with RRMS eventually transition to secondary progressive MS.
Secondary progressive MS (SPMS)
After a variable period of relapsing-remitting disease, some people enter a phase of gradual, steady worsening without distinct relapses. Many people with SPMS continue to have some relapses alongside progressive decline.
Primary progressive MS (PPMS) — ~15% of diagnoses
Gradual worsening from the outset, without initial relapses. More common in men and in those diagnosed after age 40. Fewer effective DMT options than for RRMS.
Clinically isolated syndrome (CIS)
A first episode of neurological symptoms consistent with demyelination. Not yet MS by definition — risk of developing MS depends on MRI findings at time of first episode.
Symptoms
MS symptoms depend on which part of the CNS is affected. Because lesions can occur anywhere in the brain or spinal cord, the symptom range is broad.
Fatigue
The most common and often most disabling symptom — reported by 80% of people with MS. MS fatigue is distinct from ordinary tiredness: it is disproportionate to activity level, worsens with heat, and does not reliably improve with rest. Management strategies include pacing, temperature regulation, and specific pharmacological options.
Vision changes
- Optic neuritis — inflammation of the optic nerve: pain behind the eye (worsened by eye movement), blurred or lost vision, reduced colour perception. A common early presentation of MS.
- Double vision (diplopia) — from brainstem lesions
- Nystagmus — involuntary eye movements
Motor symptoms
- Weakness or heaviness in one or more limbs
- Spasticity — muscle stiffness and spasms
- Reduced coordination, balance problems, ataxia
- Lhermitte’s sign: electric-shock sensation down the spine on neck flexion — characteristic of MS cervical cord lesion
Sensory symptoms
- Tingling, numbness, burning, or altered sensation in the limbs or face
- “MS hug” — a tight, constricting sensation around the torso from thoracic cord involvement
Bladder and bowel symptoms
- Urinary urgency, frequency, or incontinence
- Urinary retention — failure to fully empty the bladder
- Constipation
Cognitive symptoms
- Slowed information processing (“cognitive fog”)
- Difficulties with memory, attention, and multitasking
- These differ from the severe memory impairment of Alzheimer’s disease
Mood and emotional health
- Depression and anxiety are significantly more common in MS than in the general population
- Emotional lability (pseudobulbar affect) in some cases
- Adjustment to a chronic, unpredictable condition is psychologically demanding
Uhthoff’s phenomenon
Temporary worsening of symptoms with heat (hot weather, fever, hot baths) — a characteristic MS feature. This is functional, not structural worsening, and resolves with cooling.
Diagnosis
Diagnosis requires neurological expertise and cannot be made on symptoms alone.
McDonald Criteria (2017 revision)
Diagnosis requires evidence of:
- Dissemination in space (DIS): lesions in at least two of four CNS regions (periventricular, juxtacortical/cortical, infratentorial, spinal cord)
- Dissemination in time (DIT): lesions occurring at different time points
This is established by:
MRI
The cornerstone of MS diagnosis. Gadolinium-enhancing lesions represent active inflammation (blood-brain barrier disruption). T2/FLAIR lesions represent all plaques regardless of age. Spinal cord MRI adds sensitivity.
CSF analysis
Lumbar puncture may be used to detect oligoclonal bands (IgG bands in CSF not matched in blood) — present in >90% of people with MS. CSF analysis supports diagnosis when MRI is insufficient.
Evoked potentials
Measure CNS signal conduction speed. Visual evoked potentials (slowed after optic neuritis) can detect clinically silent lesions.
Blood tests
Used to exclude MS mimics: neuromyelitis optica spectrum disorder (NMOSD, anti-AQP4 antibodies), MOG antibody disease, lupus, sarcoidosis, vitamin B12 deficiency, Lyme disease.
Disease-Modifying Therapies (DMTs)
DMTs reduce the frequency and severity of relapses and slow disability accumulation in RRMS. Early initiation with appropriately effective therapy improves long-term outcomes.
Lower-efficacy DMTs (first-line in milder disease)
- Interferon beta preparations (Avonex, Betaferon, Rebif, Plegridy)
- Glatiramer acetate (Copaxone)
- Teriflunomide (oral)
- Dimethyl fumarate (oral)
These typically reduce relapse rate by 30–50%.
Higher-efficacy DMTs
- Natalizumab (Tysabri): monoclonal antibody blocking immune cell entry to CNS. Reduces relapse rate by ~70%. Risk of PML (rare but serious brain infection) in anti-JC virus antibody-positive patients requires monitoring.
- Ocrelizumab (Ocrevus): anti-CD20 therapy; effective in RRMS and the first approved DMT for PPMS
- Ofatumumab (Kesimpta): subcutaneous anti-CD20
- Cladribine (oral): immune reconstitution therapy; annual short courses
- Alemtuzumab (Lemtrada): potent immune reconstitution therapy; significant side effect profile requiring careful monitoring
Treat-to-target approach
Growing consensus favours starting with higher-efficacy therapy in those with active disease, rather than escalating slowly. This decision is individual and requires specialist input.
Management in pregnancy
Many DMTs require cessation during pregnancy. MS relapse risk increases in the postpartum period. Planning pregnancy with a neurologist and obstetrician is important.
Managing Symptoms
Fatigue management
- Pacing — planning activity to avoid “boom and bust”
- Temperature regulation — cool environments, cooling garments
- Amantadine or modafinil — some pharmacological benefit but evidence is modest
- Good sleep hygiene — see Sleep and Health
- Addressing depression and anaemia which worsen fatigue
Spasticity
- Physiotherapy — key first-line intervention
- Baclofen (oral or intrathecal pump for severe cases)
- Tizanidine
- Cannabis-based medicines (Sativex) — approved for MS spasticity in several countries
Pain
- Neuropathic pain: amitriptyline, pregabalin, gabapentin
- Musculoskeletal pain: physiotherapy, NSAIDs
Bladder
- Bladder training, pelvic floor exercises
- Antimuscarinic medications for urgency
- Self-catheterisation for retention
- Specialist urology or continence review
Depression and anxiety
- Antidepressants and psychological therapy (CBT) are effective
- These should be actively assessed and treated — not accepted as inevitable
Cognitive symptoms
- Cognitive rehabilitation, fatigue management
- Addressing reversible contributors (depression, sleep disorders, medication side effects)
Exercise and Rehabilitation
Exercise is safe and beneficial in MS. Evidence shows:
- Aerobic exercise improves fatigue, mood, and quality of life
- Resistance training reduces spasticity and improves strength
- Yoga and mindfulness improve psychological wellbeing
Heat sensitivity does not contraindicate exercise — cool environments, water-based exercise, or timing activity for cooler parts of the day are practical adaptations.
Physiotherapy and occupational therapy play central roles in maintaining function across the disease course.
Prognosis and Variability
Disease course is genuinely variable and cannot be reliably predicted for an individual at diagnosis. Factors associated with a more favourable course:
- Younger age at onset
- Female sex
- Sensory symptoms predominantly at onset (rather than motor or cerebellar)
- Low early lesion burden on MRI
- Good response to initial DMT
Modern DMTs, when started early, have substantially improved long-term outcomes compared to historical cohorts. Many people diagnosed with MS today can expect decades of maintained independence with appropriate treatment.